Reasons for Treatment Changes in Patients With Moderate to Severe Psoriasis

被引:5
|
作者
Anderson, Kathryn L. [1 ]
Feldman, Steven R. [1 ,2 ,3 ]
机构
[1] Wake Forest Sch Med, Dept Dermatol, Ctr Dermatol Res, Winston Salem, NC 27157 USA
[2] Wake Forest Sch Med, Dept Pathol, Winston Salem, NC 27157 USA
[3] Wake Forest Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA
关键词
psoriasis; phototherapy; dermatology; TREATMENT PATTERNS; DRUG SURVIVAL; BIOLOGICS; DISCONTINUATION; POPULATION; ETANERCEPT; ADALIMUMAB; CARE; IMPAIRMENT; THERAPIES;
D O I
10.1177/1203475415572797
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Psoriasis treatment involves multiple treatment arms. Treatment choice depends on many factors and may change, due to the chronicity of psoriasis. Objective: The purpose of our study is to explore reasons for treatment changes in patients with moderate to severe psoriasis. Methods: Ten charts of patients with moderate to severe psoriasis were reviewed. The medication changes and reasons for change were extracted. A treatment change was defined as switching between medication classes, adding or removing a medication class, or switching medications within the oral or biologic medication class. Results: Seventy-seven treatment changes were identified. On average, I treatment change occurred per year of follow-up. The most common reason for treatment change was inadequate disease control. Conclusions: Inadequate disease control with current therapy is the most common reason a physician changes treatment for moderate to severe psoriasis. More efficacious treatments or ways to improve efficacy may help improve the long-term outcomes of psoriasis.
引用
收藏
页码:361 / 366
页数:6
相关论文
共 50 条
  • [21] Treatment of moderate-to-severe plaque psoriasis
    Salgo, R.
    Thaci, D.
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2009, 144 (06): : 701 - 711
  • [22] Ixekizumab versus FAEs and methotrexate in treatment of nail psoriasis in patients with moderate-to-severe psoriasis
    Augustin, Matthias
    Mrowietz, Ulrich
    Willsmann-Theis, Dagmar
    Gerdes, Sascha
    Fotiou, Konstantinos
    Schuster, Christopher
    Mert, Can
    Holzkaemper, Thorsten
    Behrens, Frank
    Pinter, Andreas
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2024,
  • [23] Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus
    Langley, R. G.
    Saurat, J. H.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2012, 26 (03) : 373 - 381
  • [24] DIAGNOSIS AND TREATMENT HISTORY BEFORE PSORIASIS DIAGNOSIS AMONG PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS
    Feldman, S. R.
    Zhao, Y.
    Hur, P.
    Liu, J. S.
    Herrera, V
    VALUE IN HEALTH, 2017, 20 (05) : A156 - A156
  • [25] Reasons for discontinuation of Omalizumab therapy in the treatment of patients with moderate to severe persistent asthma
    Sheinkopf, L. E.
    Rafi, A. W.
    Do, L. T.
    Klaustermeyer, W. B.
    Katz, R. M.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (02) : S139 - S139
  • [26] Changes in patient-reported outcomes with etanercept treatment following apremilast failure in patients with moderate to severe psoriasis
    Bagel, Jerry
    Stolshek, Bradley S.
    Samad, Ahmed S.
    Yang, Yue
    Chung, James B.
    Kricorian, Gregory
    Kircik, Leon
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB180 - AB180
  • [27] COST OF MODERATE TO SEVERE PSORIASIS PATIENTS IN SPAIN
    Sanchez-Carazo, J. L.
    Dauden, E.
    Vanaclocha, F.
    Toribio, J.
    Pujol, R.
    Puig, L.
    Yebenes, M.
    Sabater, F. J.
    VALUE IN HEALTH, 2009, 12 (07) : A454 - A454
  • [28] Costeffectiveness of alefacept in patients with moderate to severe psoriasis
    Jorstad, IC
    Haugli, K
    Eggen, E
    Kristiansen, IS
    VALUE IN HEALTH, 2003, 6 (06) : 788 - 788
  • [29] Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis
    Reich, Kristian
    Nestle, Frank O.
    Wu, Ying
    Bala, Mohan
    Eisenberg, Debra
    Guzzo, Cynthia
    Li, Shu
    Dooley, Lisa T.
    Griffiths, Christopher E. M.
    EUROPEAN JOURNAL OF DERMATOLOGY, 2007, 17 (05) : 381 - 386
  • [30] STATED AND DERIVED PREFERENCES OF TREATMENT ATTRIBUTES IN MODERATE-SEVERE PSORIASIS PATIENTS
    Lee, S.
    Alcusky, M.
    Chiu, G. R.
    Deshpande, A.
    Fleming, S.
    Hadker, N.
    Lau, G.
    Vance, N.
    VALUE IN HEALTH, 2016, 19 (03) : A253 - A253